{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-114483","form_type":"8-K","ticker":"CTSO","cik":"0001175151","company_name":"Cytosorbents Corp","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.824696+00:00","generated_at":"2026-06-22T08:06:48.644100+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"CytoSorbents Q3 revenue $8.1M (-17%); pauses STAR-D trial to focus on STAR-T","bullets":["Q3 total revenue $8.1M (-17% YoY); product sales $6.5M (-27%) with negligible COVID sales.","Product gross margin 55% (64% ex-write-off) vs 82% Q3 2021; inventory write-off of ~$0.6M from equipment failure.","Pausing STAR-D trial to focus on STAR-T pivotal study; expects first milestone (40 patients enrolled) in Nov 2022; $4M cost savings in 2023.","Plans to draw $15M from existing debt before year-end; ended Q3 with $24.2M cash (incl $1.7M restricted) and no debt.","Received DoD contracts totaling ~$6.3M for HemoDefend-BGA universal plasma filter; reduced international headcount 10%."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-114483","json":"https://secwatch.observer/filing/0001104659-22-114483.json","markdown":"https://secwatch.observer/filing/0001104659-22-114483.md","text":"https://secwatch.observer/filing/0001104659-22-114483.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1175151/000110465922114483/0001104659-22-114483-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1175151/000110465922114483/tm2223902d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:06:48.644100+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4fb3f9a6425a5a9488223bf0f389a816e65eed4f","claim":"Cytosorbents Corp reported quarter ended September 30, 2022 results: revenue $8.1 million.","evidence_excerpt":"and operating results for the quarter ended September 30, 2022. Third Quarter 2022 Financial Results · Total revenue, including product sales and grant income, for Q3 2022 was $8.1 million, a decrease of 17% compared to $9.8 million in Q3 2021 · Q3 2022 product sales were $6.5 million (negligible COVID-related sales) versus $8.9 million (includes $1.1 million in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465922114483/0001104659-22-114483-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2022"},{"label":"Revenue","value":"$8.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}